Beta-Amyloid (1-40), HFIP
Beta-amyloid (A-beta) has been long reported as the major constituent of amyloid plaques in the brains of Alzheimer’s patients, and is believed by many to be the cause of Alzheimer’s Disease (AD). AD is the most common neurodegenerative disease and afflicts more than 10% of the population over 65. Recombinantly expressed and sourced from E. coli, rPeptide’s high quality beta-amyloid products offer batch-to-batch consistency and ultrapure starting material for your research needs. The HFIP (hexafluoro-isopropanol) counter-ion is a peptide which was purified before being dried with HFIP, leaving a clear dried film rather than a lyophilized powder. This counter-ion is a popular choice for researchers wishing to skip the HFIP-treatment process in their own lab while still working with a highly monomeric starting material.
- Size: 1.0 mg
- Physical State: Clear, dry film
- Temperature Storage: -20°C
- Temperature Shipping: Ambient
- Sequence:D A E F R H D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V
- Source: Recombinant. A DNA sequence encoding the human beta-amyloid (1-40) sequence was expressed in E. coli
- Purity: >97% by Mass Spec.
- Molecular Mass: 4,329 Da theoretical
References1. Yankner, B.A., et al., (1990) Science, 250 : 279-282
2. Stine, W.B., et al., (2003) J. Biol. Chem, 278 : 11612-11622
3. Frank, R.A., et al., (2003) Neurobiology of Aging, 24 : 521-536
4. Mohamed, T., (2018) ACS Chem. Neurosci., 9, 4 : 773–782
PublicationsMolecular and Cellular Neuroscience; https://doi.org/10.1016/j.mcn.2019.103390.www.ncbi.nlm.nih.gov; doi: 10.3389/fnmol.2018.00327.RSC Advances; DOI: 10.1039/C7RA02889J.Brain; doi: 10.1093/brain/awv318..PLOS ONE; DOI: 10.1371/journal.pone.0130624.ACS Publications; DOI: 10.1021/bi5010409.